Article Search

Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial

The Alliance phase II, multi-institutional trial evaluated SRS/SRT in small cell lung cancer (SCLC) patients with 1-10 brain metastases, showing a 1-year neurologic death rate of 11.0% vs 17.5% with historical whole brain radiation therapy (WBRT) controls, and a median OS of 10.2 months. Notably, only 22% required salvage WBRT, and 78% avoided WBRT entirely, with high rates of local control and manageable toxicity. The incidence of new brain mets was high (1-year: 59%), but most were managed with salvage SRS/SRT rather than WBRT. In short, for SCLC patients with limited brain mets, SRS/SRT with close MRI surveillance looks like a real alternative to upfront WBRT, potentially preserving neurocognition without compromising intracranial control.

Read More »

Keyword Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts